ADXN
NASD Addex Therapeutics Ltd Sponsored ADR$2.95 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.95
- YTD change
- -61.79%
- vs 20-day SMA
- -14.41%
- vs 200-day SMA
- -56.02%
Price ranges
Price & Performance
-3.40 (-53.54%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.6% away from all-time highs of $750.40
- ADXN is down 62% since the beginning of the year
- ADXN is down 69% over the past 12 months
- ADXN is down 25% over the past 1 month
- 0% of all ADXN investors are betting against ADXN
ADXN reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -68.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -15.71%
- vs 8-day SMA
- -11.78%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.